Two Sigma Investments LP Has $21.50 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Two Sigma Investments LP raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 88.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,843,743 shares of the company’s stock after purchasing an additional 863,363 shares during the quarter. Two Sigma Investments LP owned approximately 1.81% of Intellia Therapeutics worth $21,498,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Barclays PLC raised its position in shares of Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock valued at $6,017,000 after purchasing an additional 44,022 shares during the period. ARK Investment Management LLC grew its stake in Intellia Therapeutics by 2.3% in the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock valued at $146,174,000 after buying an additional 280,946 shares during the last quarter. SG Americas Securities LLC raised its holdings in Intellia Therapeutics by 85.7% in the 4th quarter. SG Americas Securities LLC now owns 44,838 shares of the company’s stock valued at $523,000 after acquiring an additional 20,694 shares during the period. Raymond James Financial Inc. acquired a new stake in Intellia Therapeutics during the fourth quarter worth approximately $4,793,000. Finally, Baker BROS. Advisors LP bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth approximately $7,510,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $9.20 on Thursday. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18. The firm has a market cap of $952.96 million, a price-to-earnings ratio of -1.69 and a beta of 2.33. The business’s fifty day moving average is $7.99 and its 200-day moving average is $10.67.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. During the same period last year, the business earned ($1.12) earnings per share. The business’s quarterly revenue was down 42.6% compared to the same quarter last year. As a group, research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on NTLA. Guggenheim lowered their target price on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, May 12th. The Goldman Sachs Group reiterated a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Chardan Capital reissued a “buy” rating and issued a $68.00 target price on shares of Intellia Therapeutics in a research report on Friday, May 9th. Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Wolfe Research upgraded shares of Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 price objective for the company in a research note on Monday, April 21st. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $36.90.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.